Thalidomide in ankylosing spondylitis

被引：0

作者：

Huang, F

Wei, JCC

Breban, M

机构：

[1] Hop Cochin, INSERM, U567, F-75014 Paris, France

[2] Hop Cochin, Serv Rhumatol B, F-75014 Paris, France

[3] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China

来源：

CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2002年 / 20卷 / 06期

关键词：

ankylosing spondylitis; spondylarthropathy; thalidomide; TNF alpha;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite potential side effects dominated by teratogenicity and peripheral neuropathy, thalidomide has recently been used to treat severe ankylosing spondylitis (AS). Over 50 patients have been treated across several 6-12 month open studies. Altogether 68% of the patients improved and the drop-out rate was 19%. Inhibition of NF-kappaB and/or TNFalpha is a putative mechanism for thalidomide efficacy in AS.

引用

页码：S158 / S161

页数：4

共 23 条

[11]

Corral LG, 1999, J IMMUNOL, V163, P380

[12] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[13]

El Hassani S, 1999, ARTHRITIS RHEUM, V42, pS373

[14] Thalidomide treatment for refractory Crohn's disease: a review. of the history, pharmacological mechanisms and clinical literature [J].

Ginsburg, PM ;

Dassopoulos, T ;

Ehrenpreis, ED .

ANNALS OF MEDICINE, 2001, 33 (08) :516-525

[15]

Huang F, 2000, ARTHRITIS RHEUM, V43, pS396

[16] One-year open-label trial of thalidomide in ankylosing spondylitis [J].

Huang, F ;

Gu, JR ;

Zhao, W ;

Zhu, J ;

Zhang, JL ;

Yu, DTY .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (03) :249-254

[17] Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity [J].

Keifer, JA ;

Guttridge, DC ;

Ashburner, BP ;

Baldwin, AS .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) :22382-22387

[18]

Lee L, 2001, ARTHRITIS RHEUM, V44, P2456, DOI 10.1002/1529-0131(200110)44:10<2456::AID-ART418>3.0.CO

[19]

2-V

[20] Thalidomide as an emerging immunotherapeutic agent [J].

Marriott, JB ;

Muller, G ;

Dalgleish, AG .

IMMUNOLOGY TODAY, 1999, 20 (12) :538-540

← 1 2 3 →